DiaSorin S.p.A. (BIT: DIA)
Italy
· Delayed Price · Currency is EUR | Market Cap | 5.49B |
| Revenue (ttm) | 1.16B |
| Net Income (ttm) | 167.74M |
| Shares Out | 53.32M |
| EPS (ttm) | 3.01 |
| PE Ratio | 34.18 |
| Forward PE | 24.39 |
| Dividend | 1.15 (1.14%) |
| Ex-Dividend Date | May 20, 2024 |
| Volume | 115,250 |
| Open | 99.98 |
| Previous Close | 101.10 |
| Day's Range | 99.70 - 103.00 |
| 52-Week Range | 81.24 - 106.05 |
| Beta | 0.16 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 15, 2024 |
About DiaSorin
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems... [Read more]
Financial Performance
In 2023, Pirelli & C.'s revenue was 6.91 billion, an increase of 0.18% compared to the previous year's 6.90 billion. Earnings were 479.08 million, an increase of 14.68%.
News
Diasorin 2023 revenue drops 14%, in line with guidance; shares fall
Italian medical diagnostic group Diasorin on Friday reported a double-digit drop in revenue for 2023, in line with its revenue guidance for the year, but shares dropped as much as 7.3%.
Italy's DiaSorin sees 60% plunge in COVID-19 revenue next year
Italian diagnostics firm DiaSorin forecast weaker 2022 sales and a near 60% plunge in COVID-19 revenue, with the rapid rollout of vaccines likely to bring the pandemic under control and crimp demand f...
Italian biotech company DiaSorin says its Covid-19 tests can detect omicron variant
Carlo Rosa, CEO of DiaSorin, tells CNBC that the company's Covid-19 tests can detect the omicron variant and discusses what the impact of the new variant will be on mass testing.
The Vanguard Health Care Fund's Top 5 Trades of the 3rd Quarter
The Vanguard Health Care Fund (Trades, Portfolio) recently released its portfolio updates for the third quarter of 2021, which ended on Sept. 30.
Italian Diagnostic Developer Calls Luminex a 'Perfect Fit'
Investors reacted favorably over the announcement that Saluggia, Italy-based DiaSorin SpA (MIL:DIA) is paying $1.8 billion to purchase Austin, Texas-based Luminex Corp. (NASDAQ:LMNX), a developer of p...
DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion
SALUGGIA, Italy, April 11, 2021 /PRNewswire/ -- DiaSorin S.p.A. ("DiaSorin"; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreemen...
DiaSorin Acquires COVID-19 Test Maker Luminex For $37 Per Share
Italian diagnostics firm DiaSorin SpA (OTCMKTS: DSRLF) has agreed to acquire Luminex Corporation (NASDAQ: LMNX) for $37 per share in an all-cash transaction, corresponding to a total equity value of a...
DiaSorin to acquire U.S.-based Luminex for around $1.8 billion
Shares of Italian diagnostic specialist DiaSorin surged 7% on Monday after announcing a deal to buy COVID-19 testing kit maker Luminex Corp. for around $1.8 billion. DiaSorin will pay $37 for each sha...
5 High-Quality Stocks in the Mediterranean
According to the High Quality Screener, a Premium All-in-One Screener template, five high-quality stocks based in Mediterranean countries are Diasorin SpA (MIL:DIA), Koza Altin Izletmeleri AS (IST:KOZ...